Publications en collaboration avec des chercheurs de Consejo Superior de Investigaciones Científicas (71)

2024

  1. Functional proteomics based on protein microarray technology for biomedical research

    Advances in Protein Chemistry and Structural Biology (Academic Press Inc.), pp. 49-65

2023

  1. Enhancement of Tumor Cell Immunogenicity and Antitumor Properties Derived from Platinum-Conjugated Iron Nanoparticles

    Cancers, Vol. 15, Núm. 12

  2. Exploring High-Throughput Immunoassays for Biomarker Validation in Rheumatic Diseases in the Context of the Human Proteome Project

    Journal of Proteome Research, Vol. 22, Núm. 4, pp. 1105-1115

  3. Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice

    Nature Communications, Vol. 14, Núm. 1

  4. Improving Properties of Podophyllic Aldehyde-Derived Cyclolignans: Design, Synthesis and Evaluation of Novel Lignohydroquinones, Dual-Selective Hybrids against Colorectal Cancer Cells

    Pharmaceutics, Vol. 15, Núm. 3

  5. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  6. Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study

    Cytometry Part B - Clinical Cytometry

  7. Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution

    Cancers, Vol. 15, Núm. 3

  8. The International Consensus Classification of myelodysplastic syndromes and related entities

    Virchows Archiv, Vol. 482, Núm. 1, pp. 39-51

  9. Translational research into frailty from bench to bedside: Salivary biomarkers for inflammaging

    Experimental Gerontology, Vol. 171

2022

  1. A quantitative systems approach to define novel effects of tumour p53 mutations on binding oncoprotein mdm2

    International Journal of Molecular Sciences, Vol. 23, Núm. 1

  2. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

    Blood Advances, Vol. 6, Núm. 3, pp. 774-784

  3. Comprehensive and systematic characterization of multi-functionalized cisplatin nano-conjugate: from the chemistry and proteomic biocompatibility to the animal model

    Journal of Nanobiotechnology, Vol. 20, Núm. 1

  4. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

    British Journal of Haematology, Vol. 197, Núm. 1, pp. 76-81

  5. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950

  6. Recurrent NOMO1 Gene Deletion Is a Potential Clinical Marker in Early-Onset Colorectal Cancer and Is Involved in the Regulation of Cell Migration

    Cancers, Vol. 14, Núm. 16

  7. SARS-CoV-2 Infection Triggers Auto-Immune Response in ARDS

    Frontiers in Immunology, Vol. 13

  8. Single-Cell Proteomics: The Critical Role of Nanotechnology

    International Journal of Molecular Sciences, Vol. 23, Núm. 12

  9. Systematic evaluation of plasma signaling cascades by functional proteomics approaches: SARS-CoV-2 infection as model

    Proteomics - Clinical Applications, Vol. 16, Núm. 6

  10. Transient Inhibition of the JAK/STAT Pathway Prevents B-ALL Development in Genetically Predisposed Mice

    Cancer research, Vol. 82, Núm. 6, pp. 1098-1109